ImmunoGen Inc (IMGN) Stock News
NASDAQ:IMGN - Nasdaq - US45253H1014 - Common Stock - Currency: USD
IMGN Latest News, Press Relases and Analysis
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market.
AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel
Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings.
AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A
Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., according to people with knowledge of the matter.
AbbVie revises Q1 earnings outlook as ImmunoGen deal closes (NYSE:ABBV)
AbbVie updates its earnings outlook for Q1 2024, reflecting a dilutive impact from the completed acquisition of ImmunoGen.
AbbVie Completes Acquisition of ImmunoGen
Adds flagship antibody-drug conjugate (ADC) ELAHEREĀ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRĪ±) positive platinum-resistant ovarian...
Mentions: ABBV
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.
Cassava Sciences Stock Continues Showing Rising Relative Strength
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.
ImmunoGen stock spikes as HSR period for AbbVie deal expires (NASDAQ:IMGN)
ImmunoGen's (IMGN) all-cash deal acquisition by AbbVie (ABBV) is set to be completed next week after the expiration of the Hart-Scott-Rodino waiting period. Read more here.
Mentions: ABBV
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge.
Pharma hunt antibody-drug conjugates in China (NYSE:PFE)
China has become a dominant player in the antibody-drug conjugate (ADC) race, attracting Western pharmaceutical companies for partnerships. Read more here.
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
The acquisition fills an immediate need with some extras to boot.
Mentions: ABBV
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products.
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AbbVie Q4 in focus as Humira patent cliff reaches one year
AbbVie is set to report its Q4 2023 results amid one year anniversary of biosimilar competition against its blockbuster arthritis therapy Humira. Read more here.
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
7 Dividend Aristocrats That Will Pay You for Years to Come
If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024.
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.
Is AbbVie Stock a Buy Now?
The company is grappling with losing Humira's patent protection in 2023.
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Biotech Stocks Set for Breakthroughs in 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.
What's in store for biotech M&A and IPOs in 2024? (NYSE:BMY)
Biotech M&A ended 2023 with a bang, but can investors expect the party to continue into 2024? And will the IPO market finally bounce back? Read more here.
3 Stocks at the Forefront of Medical Innovation
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.
M&A activity expected to pick up in 2024, bankers say
Merger and acquisition activity is set to rise in the coming year as borrowing becomes easier and companies are undeterred by antitrust regulators, signaling...